Skip to content

Study · Non-randomized trial · n = 16 · 2021

1 result

Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin.

da Rocha AF, Pereira Junior PS, Calefi GS, Marquezine GF, Morimoto HK, Mazzuco TL, de Faria EC, Urbano MR, Carrilho AJF

Endocrine19 Apr 2021Cited by 6 (Europe PMC)

PMID33871793 (opens in a new tab)DOI10.1007/s12020-021-02730-0 (opens in a new tab)PepBankPUB-33871793
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with prediabetes or type 2 diabetes receiving empagliflozin, added pegvisomant restored plasma β-hydroxybutyrate to baseline levels.

    In plain wordsIn patients receiving empagliflozin, added pegvisomant reduced blood ketones to baseline levels compared with empagliflozin without pegvisomant.

    Peptide
    Pegvisomant
    Outcome
    DecreasePlasma beta-hydroxybutyrate
    Study

    n = 16

    Comparator
    Empagliflozin treatment without pegvisomant
    Outcome group
    Ketogenesis · Metabolic and weight
    Studied dose
    30 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The GH receptor block by pegvisomant restored the plasma β-hydroxybutyrate to baseline levels.
    3 context sentences
    Summary · context
    Sixteen patients (11 women, 5 men) with prediabetes or type 2 diabetes mellitus, aged 55.6 ± 4.7 years and with a mean BMI of 30.7 ± 4.8 kg/m2 and HbA1c 7.1 ± 1.6% (means ± SD), participated in this study.
    Summary · context
    All of them were submitted to three mixed-meal tests: they received placebo at -60 min (test 1), and empagliflozin 25 mg (test 2, 21st day) and empagliflozin 25 mg plus pegvisomant 30 mg were administered subcutaneously 36 h before (test 3, 28th day).
    Summary · context
    After test 1, all patients were instructed to take empagliflozin 25 mg daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.